Formycon AG
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
FYB | F
Overview
Corporate Details
- ISIN(s):
- DE000A1EWVY8
- LEI:
- 39120005TZ76GQOY8Z19
- Country:
- Germany
- Address:
- Fraunhoferstraße 15, 82152 Planegg
- Website:
- https://www.formycon.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Formycon AG is a leading, independent, commercial-stage developer of biosimilars, which are high-quality, cost-effective follow-on products to off-patent biopharmaceutical medicines. As a specialized 'pure-play' biosimilar company, its activities are focused on the development of treatments in ophthalmology, immunology, and other key chronic diseases. Formycon's mission is to improve global patient access to safe and affordable biologic medicines, contributing to sustainable healthcare systems.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 06:30 |
M&A Activity
NTC becomes commercialization partner for Formycons Eylea biosimilar FYB203/Bai…
|
English | 15.2 KB | ||
| 2025-11-20 06:30 |
Regulatory Filings
Ranibizumab Biosimilar Epruvy launched in Germany
|
English | 15.7 KB | ||
| 2025-11-17 06:30 |
Regulatory Filings
Formycon achieves key development milestone with FYB208: Biosimilar candidate f…
|
English | 16.4 KB | ||
| 2025-11-14 00:00 |
Regulatory Filings
Q3 statement / Q3 financial report 2025
|
English | 227.6 KB | ||
| 2025-11-13 06:30 |
Earnings Release
Formycon publishes nine-month results and confirms guidance Pipeline progress …
|
English | 40.1 KB | ||
| 2025-10-30 06:30 |
Report Publication Announcement
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Pa…
|
English | 13.7 KB | ||
| 2025-10-21 06:30 |
Regulatory Filings
Formycons FYB201/Ranivisio sets innovative standard as Europes First Ranibizuma…
|
English | 16.6 KB | ||
| 2025-10-16 06:30 |
M&A Activity
Actor Pharmaceuticals and Megalabs become partners for the commercialization of…
|
English | 15.5 KB | ||
| 2025-10-08 09:00 |
Report Publication Announcement
|
English | 3.8 KB | ||
| 2025-10-02 06:30 |
Legal Proceedings Report
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 f…
|
English | 13.8 KB | ||
| 2025-09-30 10:16 |
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.4 KB | ||
| 2025-09-17 06:30 |
M&A Activity
Horus Pharma becomes additional commercialization partner for Formycon's Eylea …
|
English | 15.2 KB | ||
| 2025-08-13 06:30 |
Earnings Release
Formycon confirms full-year guidance following business development in line wit…
|
English | 29.9 KB | ||
| 2025-08-13 00:00 |
Interim / Quarterly Report
Half-yearly financial report 2025
|
English | 8.5 MB | ||
| 2025-07-31 13:49 |
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.4 KB |
Automate Your Workflow. Get a real-time feed of all Formycon AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Formycon AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Formycon AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-21 | Seidl, Dr. Andreas | Board | Buy | None | 4,800.00 EUR |
| 2024-04-29 | Mikulcik, Dr. Marc | Close relation | Buy | None | 48,000.00 EUR |
| 2024-04-24 | Glombitza, Dr. Stefan | Board | Buy | None | 97,444.00 EUR |
Peer Companies
